This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
CGRP receptor antagonists emerge as the most promising molecular target for neuropathic orofacial pain, with sufficient safety and mechanistic data for clinical translation.
Why it matters
Chronic face pain severely affects quality of life and has few effective treatments. Identifying validated molecular targets could lead to new therapies.
The numbers in context
Models: PTNP (nerve trauma) and PTN (root compression); targets: CGRP, inflammation, ectopic discharges, neuron-glia interactions
How the study worked
Narrative review of animal models of post-traumatic trigeminal neuropathic pain (PTNP) and primary trigeminal neuralgia (PTN), and therapeutic candidates identified therein.
Who was studied
N/A (review of PTNP and PTN animal models)
What this study cannot tell us
Review of animal models. Pain mechanisms in animals may not perfectly represent human neuropathic pain. Clinical translation is not guaranteed.
Read the original research
Potential Molecular Targets for Treating Neuropathic Orofacial Pain Based on Current Findings in Animal Models.
International journal of molecular sciences, 22(12)
Citation
Nagakura, Yukinori; Nagaoka, Shogo; Kurose, Takahiro. (2021). Potential Molecular Targets for Treating Neuropathic Orofacial Pain Based on Current Findings in Animal Models.. International journal of molecular sciences, 22(12). https://doi.org/10.3390/ijms22126406